News
Novo Nordisk Shares Post Worst Ever Week as Optimism Wanes
Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe’s most valuable public company again. Now, the stock has posted its worst week on record.
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
U.S.-listed shares of Novo Nordisk (NVO) sank roughly 20% in premarket trading after the Danish drugmaker cut its full-year ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...
Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback